An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-DFU on wound healing of diabetic neuropathic ulcer (DFU)
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs APZ 2 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors RHEACELL
- 01 Sep 2020 Status changed from recruiting to completed.
- 25 Aug 2020 Results of the phase IIa portion of this study published in the RHEACELL Media Release
- 18 Feb 2020 Planned End Date changed from 1 Sep 2019 to 1 Nov 2021.